Showing 6 posts of 6 posts found.


Gilead scoops up Immunomedics in deal worth $21 billion

September 14, 2020
Sales and Marketing Gilead, Immunomedics, acquisition, pharma

The Board of Directors from both companies have unanimously agreed for Gilead to acquire Immunomedics for $88 per share in …

FDA approves Immunomedics’ Trodelvy for metastatic triple-negative breast cancer one month ahead of schedule

April 23, 2020
Sales and Marketing Cancer, Immunomedics, Trodelvy, breast cancer, pharma

Immunomedics has scored approval with the FDA for Trodelvy (sacituzumab govitecan-hziy) in the treatment of metastatic triple-negative breast cancer, it …


Immunomedics’ whirlwind in the C-suite continues

April 10, 2018
Manufacturing and Production, Medical Communications AstraZeneca, Immunomedics, Seattle Genetics, biotech, drugs, pharma, pharmaceutical

Immunomedics hasn’t had the most straight forward year, its $2 billion deal with Seattle Genetics was scuppered by activist investors, …


Board battle scuppers Seattle Genetics’ $2 billion licensing deal

May 8, 2017
Sales and Marketing Immunomedics, Seattle Genetics, venBio

In another example of the influence that activist investors can have on the direction of a business, the potentially $2 …


Seattle Genetics’ prospective $2 billion licensing deal not without controversy

February 13, 2017
Sales and Marketing Immunomedics, Seattle Genetics, enVio

Immunomedics announced on 10 February that it had entered a licensing agreement with Seattle Genetics for its leading experimental cancer …


Immunomedics’ chief financial officer resigns, shares fall

June 22, 2016
Research and Development, Sales and Marketing Immunomedics, Shares, cfo, stock market

Shares in Immunomedics (Nasdaq: IMMU) fell as much as 11% after the company said its chief financial officer Peter Pfreundschuh …

Latest content